Locations:
SearchAdvertisement
Efficacy, safety and tolerability data shared at hematology meeting
How to combat the rise in mortality when patients become adults
Two-year event-free survival comparable to matched sibling donor myeloablative transplant
First-in-human trials of CRISPR-Cas12a gene editing demonstrate safety and meaningful event-free survival
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
First in-human trial using CRISPR/CASP 12 for gene editing in sickle cell disease
A 12-year-old patient and others in clinical trial are cured of sickle cell disease thanks to half-match donors
A primary care update
Disease-modifying medications, haploidentical transplant and gene therapies
Treating sickle cell disease sometimes takes a village
Advertisement
Advertisement